GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Asset Turnover

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Asset Turnover : 0.18 (As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Santen Pharmaceutical Co's Revenue for the three months ended in Dec. 2023 was $535 Mil. Santen Pharmaceutical Co's Total Assets for the quarter that ended in Dec. 2023 was $2,930 Mil. Therefore, Santen Pharmaceutical Co's Asset Turnover for the quarter that ended in Dec. 2023 was 0.18.

Asset Turnover is linked to ROE % through Du Pont Formula. Santen Pharmaceutical Co's annualized ROE % for the quarter that ended in Dec. 2023 was 9.81%. It is also linked to ROA % through Du Pont Formula. Santen Pharmaceutical Co's annualized ROA % for the quarter that ended in Dec. 2023 was 6.95%.


Santen Pharmaceutical Co Asset Turnover Historical Data

The historical data trend for Santen Pharmaceutical Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Asset Turnover Chart

Santen Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.61 0.61 0.59 0.59

Santen Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.17 0.19 0.17 0.17 0.18

Competitive Comparison of Santen Pharmaceutical Co's Asset Turnover

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Asset Turnover falls into.



Santen Pharmaceutical Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Santen Pharmaceutical Co's Asset Turnover for the fiscal year that ended in Mar. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=2087.596/( (3879.12+3151.021)/ 2 )
=2087.596/3515.0705
=0.59

Santen Pharmaceutical Co's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=534.978/( (2888.052+2971.354)/ 2 )
=534.978/2929.703
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Santen Pharmaceutical Co  (OTCPK:SNPHY) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Santen Pharmaceutical Co's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=203.692/2076.2475
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(203.692 / 2139.912)*(2139.912 / 2929.703)*(2929.703/ 2076.2475)
=Net Margin %*Asset Turnover*Equity Multiplier
=9.52 %*0.7304*1.4111
=ROA %*Equity Multiplier
=6.95 %*1.4111
=9.81 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Santen Pharmaceutical Co's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=203.692/2929.703
=(Net Income / Revenue)*(Revenue / Total Assets)
=(203.692 / 2139.912)*(2139.912 / 2929.703)
=Net Margin %*Asset Turnover
=9.52 %*0.7304
=6.95 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Santen Pharmaceutical Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020